Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
M3MTHRY -2.65%82 Cash-to-Debt is 5.64 as of Mar. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates MTHRY with a GF Score™ of 82/100 and a GF Value™ of $8.44 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 670 Healthcare Providers & Services companies, M3 ranks better than 74.63% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. M3's cash to debt ratio for the quarter that ended in Mar. 2026 was 5.64.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, M3could pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for M3's Cash-to-Debt or its related term are showing as below:
MTHRY'
s Cash-to-Debt Range Over the Past 10 Years
Min: 4.94 Med: No Debt Max: No Debt
Current: 4.94
During the past 13 years, M3's highest Cash to Debt Ratio was No Debt. The lowest was 4.94. And the median was No Debt.
MTHRY's Cash-to-Debt is ranked better than 74.63% of 670
companies
in the Healthcare Providers & Services industry
Industry Median: 0.785
vs MTHRY: 4.94
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
M3 Cash-to-Debt Related Terms
M3 Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for M3's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Health Information Services subindustry, M3's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
M3 Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, M3's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where M3's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
M3 (MTHRY) has a Cash-to-Debt of 5.64 as of Mar. 2026. This is 100% below median its historical median of 10,000.00. Over the past decade, M3's Cash-to-Debt has ranged from 4.94 to 10,000.00. According to the industry distribution chart, M3 ranks #170 out of 670 companies in the Healthcare Providers & Services industry, placing it in the top 25.4%.
Is M3's Cash-to-Debt too high?
M3's current Cash-to-Debt of 5.64 is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 4.94 to a high of 10,000.00. The Healthcare Providers & Services industry median Cash-to-Debt is 0.79. M3's value of 5.64 is 618.5% above this industry median. Based on the distribution chart, M3 ranks #170 out of 670 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, M3 has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does M3's Cash-to-Debt compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, M3 ranks #170 out of 670 companies for Cash-to-Debt. This puts M3 in the upper half of its industry. The industry median Cash-to-Debt is 0.79. M3's value of 5.64 is 618.5% above this benchmark. Historically, M3's own Cash-to-Debt has ranged from 4.94 to 10,000.00 over the past decade. While the company's 10-year median is 10,000.00 vs. the industry median of 0.79, M3 has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.79, based on 670 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. M3's current Cash-to-Debt of 5.64 is 618.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. M3's current Cash-to-Debt is 5.64, which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is M3 stock overvalued right now?
Based on GuruFocus' analysis, M3 (MTHRY) is currently considered Significantly Undervalued. The stock's GF Value™ is $8.44, compared to a current price of $5.50 — trading 34.8% below its estimated fair value. The current Cash-to-Debt is 5.64, which is 100% below median its 10-year median of 10,000.00 and 618.5% above the Healthcare Providers & Services industry median of 0.79. M3's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For M3 (MTHRY), the current Cash-to-Debt is 5.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is M3 (MTHRY) Overvalued in 2026?
Based on GuruFocus' analysis, M3 stock appears to be undervalued.
The current stock price of $5.50 is trading 34.8% below its estimated GF Value™ of $8.44.
GuruFocus considers M3 to be Significantly Undervalued.
Key valuation signals for MTHRY:
Cash-to-Debt: 5.64 (100% below median its 10-year median of 10,000.00)
GF Value™: $8.44 vs. price of $5.50 (34.8% below fair value)
Industry Position: 618.5% above the Healthcare Providers & Services median (#170 of 670)
No single metric tells the full story. See the MTHRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
M3 Inc is a Japan-based company engaged in providing medical-related services through internet-based platforms and real-world operations. The company operates six reportable segments: Medical Platform, Evidence Solutions, Career Solutions, Site Solutions, Patient Solutions, and Overseas. Its businesses include online marketing for medical professionals, clinical trial support, human resources services for medical professionals, operational support for medical institutions, and patient support services. The Overseas segment offers similar services internationally, including in the United States, the United Kingdom, China, South Korea, India, France, Germany, and Spain.
82GF Score
Get the complete analysis for MTHRY
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MTHRY has been successfully added to your 
